All In MedTech

Device Trial Radar · NCT01630707

Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack

MultiCenter Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy in Patients With Anterior Acute Myocardial Infarction ≤ Six Hours After Symptom Onset and Successful Reperfusion (Via PCI)

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Aug 2012

Primary completion

Sep 2013

Study completion Aug 2014

Sponsor

Lead sponsor
TherOxNot on our public-company list
Sponsor type
Industry
First posted
Jun 28, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the feasibility of the delivery of SuperSaturated Oxygen (SSO2) Therapy for 60 minutes selectively into the left main coronary artery (LMCA). The therapy will be delivered with a commercially available qualified SSO2 delivery catheter used with the TherOx® DownStream® System and Cartridge in the treatment of patients presenting with an anterior acute myocardial infarction (heart attack) ≤ six hours after symptom onset with successful reperfusion (via PCI).

Conditions

  • Anterior Wall Acute Myocardial Infarction

Interventions

  • SuperSaturated Oxygen (SS02) TherapyDevice

    Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Feasibility of Intracoronary Infusion of SSO2 TherapyTime frame: Procedure

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Scottsdale Healthcare

    Scottsdale, Arizona

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.